Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1130620190150040488
Journal of Clinical Neurology
2019 Volume.15 No. 4 p.488 ~ p.495
Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease
Wang Hung-Li

Lu Chin-Song
Yeh Tu-Hsueh
Shen Yu-Ming
Weng Yi-Hsin
Huang Ying-Zu
Chen Rou-Shayn
Liu Yu-Chuan
Cheng Yi-Chuan
Chang Hsiu-Chen
Chen Ying-Ling
Chen Yu-Jie
Lin Yan-Wei
Hsu Chia-Chen
Lin Huang-Li
Chiu Chi-Han
Chiu Ching-Chi
Abstract
Background and Purpose: It is essential to develop a reliable predictive serum biomarker for Parkinson's disease (PD). The accumulation of alpha-synuclein (¥áSyn) and up-regulated expression of Rab35 participate in the etiology of PD. The purpose of this investigation was to determine whether the combined assessment of serum ¥áSyn and Rab35 is a useful predictive biomarker for PD.

Methods: Serum levels of ¥áSyn or Rab35 were determined in serum samples from 59 sporadic PD patients, 19 progressive supranuclear palsy (PSP) patients, 20 multiple system atrophy (MSA) patients, and 60 normal controls (NC). Receiver operating characteristics (ROC) curves were calculated to determine the diagnostic accuracy of ¥áSyn or/and Rab35 in discriminating PD patients from NC or atypical parkinsonian patients.

Results: The levels of ¥áSyn and Rab35 were increased in PD patients. The serum level of Rab35 was positively correlated with that of ¥áSyn in PD patients. Compared to analyzing ¥áSyn or Rab35 alone, the combined analysis of ¥áSyn and Rab35 produced a larger area under the ROC curve and performed better in discriminating PD patients from NC, MSA patients, or PSP patients. When age was dichotomized at 55, 60, 65, or 70 years, the combined assessment of ¥áSyn and Rab35 for classifying PD was better in the group below the cutoff age than in the group above the cutoff age.

Conclusions: Combined assessment of serum ¥áSyn and Rab35 is a better biomarker for discriminating PD patients from NC or atypical parkinsonian patients, and is a useful predictive biomarker for younger sporadic PD patients.
KEYWORD
Parkinson's disease, serum, biomarker, alpha-synuclein, Rab35
FullTexts / Linksout information
 
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø